Entrada Therapeutics Plunges 57% as Duchenne Muscular Dystrophy Study Data Misses Key Dystrophin Target
Summary
Entrada Therapeutics' shares plunged 57% after the market reacted negatively to detailed Cohort 1 data from its Phase 1/2 ELEVATE-44-201 study for ENTR-601 in Duchenne Muscular Dystrophy. Despite an earlier announcement of 'positive topline results' and favorable safety, the specific data revealed a significant miss on dystrophin production, with only a 2.36% increase against prior expectations for double-digit levels. This critical detail, which was not fully appreciated in the initial positive headline, triggered a sharp sell-off. The market's disappointment with the dystrophin levels has materially narrowed the investment thesis, placing increased importance on the upcoming Cohort 2 data expected later this year.
At the time of this announcement, TRDA was trading at $6.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.3M. The 52-week trading range was $4.93 to $16.45. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.